News | Coronavirus (COVID-19) | March 24, 2020

CDRH Issues Letter to Industry on COVID-19

The FDA issued a Letter to Industry that includes steps the FDA’s Center for Devices and Radiological Health (CDRH) has taken to prioritize work that advances the nation’s response during the Coronavirus Disease 2019 (COVID-19) public health emergency

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

March 24, 2020 — The U.S. Food and Drug Administration (FDA) issued a Letter to Industry that includes steps the FDA’s Center for Devices and Radiological Health (CDRH) has taken to prioritize work that advances the nation’s response during the Coronavirus Disease 2019 (COVID-19) public health emergency.

These steps seek to address the impact of the COVID-19 public health emergency on day-to-day operations in CDRH and in the medical device industry, while ensuring that government and private sector efforts to respond to this national emergency receive the highest priority.

The letter, dated March 23, 2020, reads as follows:

In response to the Coronavirus Disease 2019 (COVID-19) public health emergency,1 FDA’s Center for Devices and Radiological Health (CDRH) has taken the steps described in this letter to prioritize work that advances the nation’s response during this national emergency.2 These steps seek to address the impact of the COVID-19 public health emergency on day-to-day operations in CDRH and in the medical device industry, while ensuring that government and private sector efforts to respond to this national emergency receive the highest priority.

CDRH Has Converted In-Person Meetings with Industry to Teleconferences

Where possible, CDRH is leveraging technology to host teleconferences rather than in-person meetings with industry scheduled through April 30, 2020. We are converting each meeting to a teleconference to be held at the same date and time. We believe we have contacted all parties with meetings scheduled through April 30, 2020 to provide teleconference information. If you have not received teleconference information, please reach out to the CDRH staff member who originally scheduled your meeting. We will continue to assess whether any in-person meetings scheduled later than April 30, 2020 should be converted to teleconferences and will provide periodic updates.

Processing of Incoming Documents

The Document Control Center continues to receive and process incoming documents. In order to ensure the security of your information, we are generally unable to accept incoming submissions via email. In addition, existing systems have file size limitations associated with email. We are looking into electronic options other than email. We regret any delays this may cause you.

Extension of Response Due Dates for Marketing Applications Currently on Hold

For marketing applications on hold as of March 16, 2020, where the response due date is on or before April 30, 2020, CDRH has extended response due dates by 60 days for Premarket Notifications (510(k)s), Premarket Approval (PMA) applications (original and supplements), Humanitarian Device Exemption (HDE) applications (original and supplements) and De Novo classification requests. CDRH intends to extend this due date automatically; no extension requests are necessary to be submitted.

For additional submission types where a response or report is due (e.g., Post Approval or 522 Study reports, Investigational Device Exemption annual reports, PMA reports), we encourage you to submit the response or report when possible.

Please address any questions about response due dates to [email protected].

How to Submit an Inquiry or Request for an Emergency Use Authorization

On Fe. 4, 2020, the HHS Secretary determined that there is a public health emergency that involves the virus that causes COVID-19. On that same date, the Secretary declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 and on March 4, 2020, the Secretary made the declaration with respect to personal respiratory protective devices. Under FDA’s emergency use authorities, the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in certain emergencies to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives. We strongly encourage applicants to submit pre-EUAs to discuss technologies that might help address this emergency.

More information about current EUAs is on the FDA’s Emergency Use Authorization web page. For inquiries related to EUAs for in vitro diagnostics (IVDs), contact [email protected] For inquiries related to EUAs related to non-IVD medical devices, contact [email protected] For more information about the EUA program, please see the guidance, Emergency Use Authorization of Medical Products and Related Authorities.

COVID-19 Related Guidance Documents

FDA has issued immediately in effect guidance documents related to COVID-19. For the latest information, please see the FDA’s COVID-19 Related Guidance Documents web page.

 

References:

1 On January 31, 2020, the Secretary of Health and Human Services Alex M. Azar, issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS, Determination that a Public Health Emergency Exists. Jan. 31, 2020. (Accessible at https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx. 2 On March 13, 2020, the President declared a national emergency in response to COVID-19. President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19). Mar. 13, 2020. (Accessible at https://www.whitehouse.gov/presidential-actions/proclamation-declaring-national-emergency-concerningnovel-coronavirus-disease-covid-19-outbreak/). U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov

Related Coronavirus Content:

Qure.ai Launches Solutions to Help Tackle COVID19 

ASRT Deploys COVID-19 Resources for Educational Programs

Study Looks at CT Findings of COVID-19 Through Recovery

VIDEO: Imaging COVID-19 With Point-of-Care Ultrasound (POCUS)

The Cardiac Implications of Novel Coronavirus

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

Radiology Lessons for Coronavirus From the SARS and MERS Epidemics

Deployment of Health IT in China’s Fight Against the COVID-19 Epidemic

Emerging Technologies Proving Value in Chinese Coronavirus Fight

Radiologists Describe Coronavirus CT Imaging Features

Coronavirus Update from the FDA

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Chest CT Findings of Patients Infected With Novel Coronavirus 2019-nCoV Pneumonia 

Find more related clinical content Coronavirus (COVID-19)

Related Content

News | Breast Imaging | September 20, 2021
September 20, 2021 — ImageCare Centers is unveiling its new “PINK Better Mammo” service with the addition of...
Shimadzu Medical Systems USA, a leading manufacturer of advanced medical X-ray imaging systems, has announced that the Trinias unity edition product line has been awarded a contract from Vizient, Inc., a healthcare performance improvement company, effective Sept. 1, 2021.
News | X-Ray | September 17, 2021
September 17, 2021 — Shimadzu Medical Systems USA, a leading manufacturer of advanced medical...
Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI

Getty Images

News | Contrast Media Injectors | September 16, 2021
September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthc
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
This is an example of 3-D ultrasound imaging on a breast, designed to help increase efficiency and diagnostic accuracy in any practice. Image courtesy of Hologic.

This is an example of TriVu ultrasound imaging on a breast, designed to help increase efficiency and diagnostic accuracy in any practice. Image courtesy of Hologic.

Feature | Breast Imaging | September 15, 2021 | By Jennifer Meade
The...
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.

Getty Images

News | Lung Imaging | September 15, 2021
September 15, 2021 — Revised guidelines for...
To get more flexibility and cost savings from storage, healthcare organizations are increasing their investments in the cloud
Feature | Information Technology | September 15, 2021 | By Kumar Goswami
Healthcare organizations today are storing petabytes of medical imaging data — lab slides,...
Revenues for teleradiology reading service providers are forecast to follow a similar profile over this period.

Outlook for 2021 and Beyond. As displayed in the figure below, these six market drivers are projected to result in teleradiology reading service volumes increasing by 21% in 2021 and nearly doubling by 2025. Revenues for teleradiology reading service providers are forecast to follow a similar profile over this period.

Feature | Teleradiology | September 15, 2021 | By Arun Gill
The closely tied relationship between...